IPCI (MCAP $42 M) = AWAITING 8 FDA APPROVALS WITHIN 1 YEAR // FIRST APPROVAL THIS MONTH
A REAL LIFETIME OPPORTUNITY HERE FOLKS .....Do your own DD and realize the Mega Potential !
FIRST FDA APPROVAL EXPECTED FOR THIS MONTH ....
This Unknown LOW FLOAT Stock awaiting 8 FDA approvals.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including two Potential Blockbuster .CEO is the largest Shareholder with over 6 Million Shares .
6x FDA APPROVALS COMING WITHIN NEXT 12 MONTHS = NEXT BILLION DOLLAR COMPANY HERE !
Patience here will payoff big time ! GLTA
Market Cap:$ 42 M
Shares Out: 17.7 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 6 M
Intellipharmaceutics is still awaiting FDA approval for generic Focalin XR, but we note that the FDA has not requested any new information within the past three months related to Focalin XR’s ANDA. We still expect approval in the near term and, once approved, partner Par Pharmaceutical can market generic versions of 5, 10, 15, and 20mg Focalin XR (U.S. revenue for Focalin XR from 4Q11 – 3Q12 was about $601 million).The generic companies expect the FDA to approve these generic versions by the fourth quarter of 2012.
Intellipharmaceutics has now announced eight ANDAs as having been filed with the FDA, with reported sales by others for branded and generic versions of these products being approximately $4.5 billion for the 12 months ended July 2012. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway. There can be no assurance as to whether or when the FDA will approve any Intellipharmaceutics' application.